Nasal spray that helps protect against covid-19 – ENOVID NASAL SPRAY 25 ML’



We V hand is a nasal spray with antiviral properties that destroys viruses and creates a physical barrier that prevents viruses from entering the body. Anobid has been scientifically tested and proven to kill 99.9% of viruses in the respiratory tract within 2 minutes. We are clinically tested and found to be safe for use in humans. Nasal spray against viruses approved by the Ministry of Health.

Nasal spray that helps protect against corona – ENOVID  NASAL SPRAY Buy online

‘Life-saving’ nose spray that kills 99.9% of viruses begins production in Israel

Health Ministry-approved labeling says antiviral is effective within 2 minutes; can save many lives in countries without access to vaccines, says inventor

Even if you get infected, you can help it not start in Corona!

An innovative nasal spray that helps protect against viruses. Tested and laboratory tested to kill 99.9% of viruses within 2 minutes.
-Registered patent –

Results from experiments conducted in the UK indicate that the innovative nasal spray was able to reduce the concentration of viruses  among verified corona patients by 95% within 24 hours and 99% within 72 hours.
A registered anti-viral antiviral nasal spray made in Israel that is found to be effective against the corona virus.
Anobid spray was developed in Canada by SaNOtize (a biotechnology company) and manufactured in Israel.
The spray is also effective against other respiratory viruses such as those that cause the flu.
The spray can be used up to 5 times a day after coming in contact with viruses.
Suitable for adults and children over the age of 12.
Capacity of 25 ml vial, suitable for personal use for about a month.
For daily use.

Approved by the Ministry of Health (approved by AMR).


The nose is a major source of penetration and culture for various viruses that pass through the breath. Destruction of the viruses while they are still in the nose ensures that they are almost completely prevented from becoming infected. The purpose of a nasal spray against viruses is to kill the virus as soon as it enters the body, in the airways, instead of fighting it after it has already spread to other areas.
Dr. Gili Regev, Israeli CEO and founder of SaNOtize (the Canadian company that developed the spray) called Enovid a “hand disinfectant for the nose”, saying it creates a physical barrier in the nasal passages to stop viruses along with a “chemical barrier” of nitric oxide , Known for its antimicrobial properties. According to Regev: “Nitric oxide indicates that it is a special spray that not only blocks viruses but actually kills them.”
Because most corona infections are in the nose, SaNOtize believes this is an effective way to reduce the spread of Corona virus infection.
Nitrous spray uses nitric oxide as a chemical and mechanical barrier against a viral infection in the nose, where respiratory diseases such as corona infiltrate the body.

Anobid spray can suppress SARS-CoV-2 virus in 2 minutes.

When to use anubid?
Recommended for use before / after contact or exposure to viruses from people and in inventions in high-risk environments (such as public transportation / flights / staying with a sick or isolated person, multi-participant events, etc.).
Can be used 2-3 times a day or up to 5 times a day on suspicion of exposure to viruses.
Anobid anti-virus nasal spray has been tested and proven in the laboratory
The spray was tested in independent laboratory tests in the United States, at the University of Utah Research Center, where the high level of efficacy was found: 99.9% success in killing the virus.
Clinical trials conducted in the UK and Canada suggest that it is a safe and effective antiviral treatment that can significantly lower the concentration of the virus in verified patients, prevent the transmission of the corona COVID-19 virus, shorten the course of the disease and reduce its severity.
The spray has also been shown to be effective in dealing with variants.
In a randomized trial evaluating corona cases, early anubid treatment significantly reduced the level of SARS-CoV-2 virus, including in patients with high viral load.
The average decrease in virus entry in the first 24 hours was 1.362, which corresponds to a decrease of about 95%.
Within 72 hours, the viral load decreased by more than 99%.
Most of these patients have contracted the British version, the more worrying.
The data were published in the Journal of Infection:


Before purchasing a product or medical preparation and starting to use it, it is advisable to consult a qualified health care professional regarding the purposes of using the product, how to use it, its side effects and its interaction with other medical preparations. The consumer leaflet should be read before using a medicinal product. The information on the Main Health website does not serve as an opinion or medical guideline and cannot be used as a substitute for consulting a doctor / physiotherapist / nutritionist / occupational therapist / pharmacist and / or other qualified specialist.

Each of the product suppliers on the site determines the shipping costs in accordance with its decision, the product supplier may hold a sale on the site that includes a credit and cancellation of the shipping fee. If the order includes products from different suppliers, the customer will pay a shipping fee for each order separately in accordance with the decision of the various suppliers.

There is no professional advice in the field of accessibility in the phone call, in order to purchase the product. In any case of hesitation about the degree of suitability of the product we recommend getting professional advice from a qualified accessibility consultant.

Enovid, a new nasal spray that counteracts SARS-CoV-2, among other viruses, is now on sale in Israel.

Although Israel approved Enovid as a medical device with a claim to protect from viruses, Phase II clinical trials in the United Kingdom found statistically significant evidence that the spray can prevent the transmission of the coronavirus and reduce the viral load and severity of symptoms in those already infected with the virus.

Developed by SaNOtize, a Canadian biotech startup co-founded by Israeli scientist Dr. Gilly Regev and Dr. Chris Miller, the spray has also been approved for sale in Bahrain.

Marketed as a “hand sanitizer for the nose,” SaNOtize’s laboratory testing of Enovid found it capable of killing 99.9% of live viruses within two minutes. When it went on sale this month, its initial stock of supplies sold out of Israeli pharmacies in two days, Regev said.

“I really hope this is a good case study to show the world what a product like this can do,” Regev told the Forward.

As the Delta variant spreads, Enovid could provide a promising solution to slow transmission among the vaccinated and unvaccinated alike. “With the current increase in infections due to lower efficacy of the vaccine with the Delta variant, the combination of the nasal spray with the vaccine will give people much stronger protection,” Regev said.

SaNOtize has not yet tested Enovid on the Delta variant specifically. However, Regev expects the nasal spray to work against it. “It’s a general antiviral. We tested it on influenza, we tested it on rhinovirus, we tested it on RSV,” she said. “It works on all these viruses and their variants. There’s absolutely no reason to believe it’s not going to be effective against the Delta [variant] as well.”

Each bottle, which costs approximately $59, contains enough of the nasal spray for one adult to administer it twice a day for one month. SaNOtize is actively trying to cut production costs and lower the price, Regev said.

With interest in Enovid from around the world, SaNOtize is preparing to scale up manufacturing. Regev anticipates that the product will be approved for sale in many other countries within the next few months, she said.

The ingredients in Enovid combine to release nitric oxide, a substance that kills viruses in the nasal passages. “All components are used widely in the food industry and have a very strong safety profile,” Regev said.

Regev and Miller initially started developing liquid formations of nitric oxide 13 years ago with the goal of creating a flu preventative, which was difficult to prove was effective, Regev said. They had moved on to developing treatments for chronic sinusitis and diabetic foot ulcers, but returned to the antiviral nasal spray idea at the start of the pandemic.

Regev sees the antiviral nasal spray becoming part of a typical hygiene routine, as hand sanitizer has. “Some people will only use it when they’re on a flight or at a concert or on a train with many people, but some will really adopt it as a daily routine to prevent getting sick.”

Having used the nasal spray herself for the past few years, Regev had anecdotal evidence of its efficacy before the clinical trials. “I used to get sick after every flight. I just started using it as a routine when I got on the plane and when I got off the plane, and I stopped getting sick,” she said.

Currently in the midst of two Phase III clinical trials, SaNOtize is testing whether Enovid can reduce hospitalizations. “The goal is for us to collect all the data and show that this is really effective. We do know that it kills viruses, and we do know that the infection starts in the nose. We do know that we’ve already reduced viral load in humans in the nose,” Regev said. “We’ve got quite a lot of data but we can keep collecting data.”


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.